Edmund Chiong

Chiong Edmund

Appointment(s)
  • Associate Professor, Department of Surgery
  • Senior Consultant, Division of Surgical Oncology, National University Cancer Institute, Singapore, National University Health System
  • Senior Consultant, Department of Urology, University Surgical Cluster, National University Health System
Administrative Appointment(s)
  • Director, Urologic Oncology, Department of Urology, University Surgical Cluster,  National University Health System
  • Director of Research, Department of Urology, University Surgical Cluster, National University Health System
  • Associate Chairman, Medical Board (Research), National University Health System
Academic Qualifications
  • PhD, National University of Singapore, Singapore
  • MBBS, National University of Singapore, Singapore
  • FRCSEd, The Royal College of Surgeons of Edinburgh, United Kingdom
  • FRCSI, The Royal College of Surgeons of Ireland, Ireland
  • FAMS, Academy of Medicine, Singapore
Research Interest(s)
  • Bladder Cancer
  • Prostate Cancer
  • Cancer Diagnostics and Therapeutics
  • Medical Device Innovation
  • Urinary Tract Infections
Recent Publications
  • 1. Wang R, Neoh KG, Kang ET, Tambyah PA, Chiong E. 2015 Apr. Antifouling coating with controllable and sustained silver release for long-term inhibition of infection and encrustation in urinary catheters. J Biomed Mater Res B Appl Biomater. 103(3):519-28. doi: 10.1002/jbm.b.33230. 24922113.
  • 2. Chan EC, Pasikanti KK, Hong Y, Ho PC, Mahendran R, Raman Nee Mani L, Chiong E, Esuvaranathan K. 2015 Feb. Metabonomic profiling of bladder cancer. J Proteome Res. 14(2):587-602. doi: 10.1021/pr500966h. 25388527.
  • 3. Chittezhath M, Dhillon MK, Lim JY, Laoui D, Shalova IN, Teo YL, Chen J, Kamaraj R, Raman L, Lum J, Thamboo TP, Chiong E, Zolezzi F, Yang H, Van Ginderachter JA, Poidinger M, Wong AS, Biswas SK. 2014 Nov. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity. 41(5):815-29. doi: 10.1016/j.immuni.2014.09.014. 25453823.
  • 4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. 2014 Jul. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 371(5):424-33. doi: 10.1056/NEJMoa1405095. 24881730.
  • 5. Zhang Q, Neoh KG, Xu L, Lu S, Kang ET, Mahendran R, Chiong E. 2014 Jun. Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir. 3;30(21):6151-61. doi: 10.1021/la500746e. 24824061.